A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer

被引：379

作者：

Cobleigh, MA

Langmuir, VK

Sledge, GW

Miller, KD

Haney, L

Novotny, WF

Reimann, JD

Vassel, A

机构：

[1] Rush Presbyterian St Lukes Med Ctr, Chicago, IL 60612 USA

[2] Genentech Inc, San Francisco, CA USA

[3] Indiana Univ, Indianapolis, IN 46204 USA

来源：

关键词：

D O I：

10.1053/j.seminoncol.2003.08.013

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：117 / 124

页数：8

共 20 条

[1] Borgström P, 1999, ANTICANCER RES, V19, P4203
[2] EXPRESSION OF VASCULAR-PERMEABILITY FACTOR (VASCULAR ENDOTHELIAL GROWTH-FACTOR) AND ITS RECEPTORS IN BREAST-CANCER
BROWN, LF
BERSE, B
JACKMAN, RW
TOGNAZZI, K
GUIDI, AJ
DVORAK, HF
SENGER, DR
CONNOLLY, JL
SCHNITT, SJ
[J]. HUMAN PATHOLOGY, 1995, 26 (01) : 86 - 91
[3] BROWN LF, 1997, EXS, V79, P233, DOI DOI 10.1007/978-3-0348-9006-9_10
[4] DEVORE RF, 2000, P AN M AM SOC CLIN, V19, P485
[5] Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene
Ferrara, N
CarverMoore, K
Chen, H
Dowd, M
Lu, L
OShea, KS
PowellBraxton, L
Hillan, KJ
Moore, MW
[J]. NATURE, 1996, 380 (6573) : 439 - 442
[6] Ferrara N, 1999, CURR TOP MICROBIOL, V237, P1
[7] FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182
[8] CLINICAL IMPORTANCE OF THE DETERMINATION OF TUMOR ANGIOGENESIS IN BREAST-CARCINOMA - MUCH MORE THAN A NEW PROGNOSTIC TOOL
GASPARINI, G
HARRIS, AL
[J]. JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (03) : 765 - 782
[9] Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer
Gordon, MS
Margolin, K
Talpaz, M
Sledge, GW
Holmgren, E
Benjamin, R
Stalter, S
Shak, S
Adelman, DC
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (03) : 843 - 850
[10] Granger JP, 2000, ACTA PHYSIOL SCAND, V168, P161